Double Hit Lymphoma (DHL)
Triple Hit Lymphoma (THL)

2017-04-01   Anwar N Mohamed 

1.Cytogenetics Laboratory, Pathology Department, Detroit Medical Center, Wayne State University School of Medicine, Detroit, MI USA; amohamed@dmc.org

Abstract

The role of cytogenetics in identification of double-hit lymphoma, a subset of a high grade large B-cell lymphoma.

Clinics and Pathology

Disease

Double-hit lymphoma (DHL), triple-hit lymphoma (THL), diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBL) with MYC, BCL2 and/or BCL6 rearrangements

Epidemiology

The DH lymphoma most commonly affects elderly patients with a median age of 62-74 years (range 18-96 years), and both sexes are affected with a slight male predominance. The incidence of DH genotype has been difficult to assess because fluorescence in situ hybridization (FISH) studies have not been used widely on unselected series, and the published data may be biased toward a specific type of lymphoma. Nevertheless, DH lymphoma has been reported in 5-15% of patients with DLBCL and aggressive B-cell lymphoma. Comprehensive analysis of Mitelman Database of Chromosome Aberrations in Cancer (Aukema et al, 2011, Oliveira et al 2017), DH lymphomas with breaks at MYC, BCL2 and/or BCL6 regions were identified in 14% of DLBCL cases; 62% of those involved MYC and BCL2 sites, 18% involved MYC and BCL6 while the remaining cases had triple translocations. Using FISH, Barrans et al (2010) identified DH and TH genotypes in 12% cases with de novo DLBCL; the majority of these cases had BCL2 and MYC translocations (66%), BCL6 and MYC breaks in 10% and breaks in all three sites in 24% of cases. MYC and BCL2 translocations are also found in a small proportion of follicular lymphoma. We identified MYC breaks in 7% of t(14;18)-bearing follicular lymphoma cases; all described to have a high grade morphology with Burkitt-like or blastic morphology replacing residual follicles (Mohamed et al, 2001). Pedersen et al have reported that in transformed lymphoma, DH genotype was very frequent found in 21% of cases; all had follicular lymphomas (Pedersen et al 2012).

Clinics

Patients with DH lymphomas commonly have an aggressive clinical course, characterized by advanced stage disease, extranodal involvement, and high serum lactate dehydrogenase levels. The extranodal sites include the bone marrow, central nervous system, gastrointestinal tract, liver, spleen, lung, pleural fluid, testis, ovaries, skin, and thyroid gland. Bone marrow is involved in about 50% of patients and many have a leukemic disease. The International Prognostic Index score (IPI score) is often intermediate-high or high (Barrans et al 2010, Petrich et al 2014). Most patients have a de novo disease while a minority (10%) present with a history of a low-grade follicular lymphoma or other B-cell lymphoma, then develop DHL presumably by the acquisition of MYC rearrangement.
Double Expresser lymphoma
Immunohistochemistry (IHC) has identified a fraction of DLBCL cases with high expression of MYC and BCL2 proteins (Perry et al 2014, Mahmoud et al 2015). These double expresser lymphomas (DE) are lacking MYC and BCL2 translocations and are usually of non-GC types. DE lymphomas are much more common than DH lymphomas, with approximately 30% of DLBCL being reported as DE lymphomas. Most studies use a cutoff of 40% for MYC IHC and a cutoff of 70% for BCL2 to define DE lymphoma (Green et al 2012 A). Clinically, the DE lymphomas have more aggressive clinical course than those lacking MYC and BCL2 protein expression.

Pathology

Because DHL is genotypically defined; it is not restricted to a specific histology subtype. Most tumors are medium to large in size, with atypical morphology and very high proliferation rate. Previously, DH lymphomas were diagnosed as diffuse large B-cell lymphoma (DLBCL), aggressive B-cell lymphoma not otherwise specified (NOS) or Burkitt-like lymphoma. Rare cases were classified as lymphoblastic lymphoma. The increase recognition of these lymphomas led the 2008 WHO classification of hematopoietic and lymphoid neoplasms to introduce a provisional category of "B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL", (BCLU) to recognize a subset of very aggressive lymphoma in which the distinction between DLBCL and

Treatment

Standard therapies such as R-CHOP developed for patients with DLBCL are less effective in DHL, with a median overall survival of 12 months or less, as the majority of patients experience disease progression. Currently, more, intensive chemotherapy such as dose adjusted R-EPOCH therapy, is being evaluated which appears to be effective in many DH lymphoma patients. Consideration for frontline stem cell transplant in responding patients are also suggested (Oki et al 2014, Petrich et al 2014, Dunleavy 2015).

Prognosis

Patients with classic, FISH-defined DH lymphomas have a very poor prognosis, usually present with high clinical risk factors, such as high IPI scores and bone marrow involvement. The outcome is dismal with rare long term survival after standard therapy (Perry et al 2014, Petrich et al 2014, Oki et al 2014). Several recent studies have indicated that the outcome of DE lymphomas, as defined by IHC is inferior to that of DLBCL but better than that of DH lymphomas. Therefore, the co-expression of MYC and BCL2 proteins in DLBCL is considered a prognostic biomarker of an inferior outcome (Green et al, 2012 B).

Cytogenetics

Note

t(8;14)(q24;q32), t(14;18)(q32;q21), t(3;14)(q27;q32) and variants.
Atlas Image
Figure 1: Complex karyotype from a double hit lymphoma showing t(14;18)(q32;q21) and add(8)(q24)

Cytogenetics morphological

Double-hit lymphomas are usually seen in the context of a complex karyotype containing multiple numerical and structural aberrations (Figure 1). Over 2/3 of cases demonstrate dual translocations involving 8q24/MYC and t(14;18)/BCL2 breakpoints. Less commonly the translocations implicate 8q24/MYC and 3q27/BCL6 sites and rare cases have breaks in all three sites, referred to a "triple hit" lymphoma. The partner gene(s) involved in MYC/8q24 translocations are the IG genes in about of 60% of DHL cases; more frequently affecting the IG light chain loci 22q12/IG lambda and 2p12/IG kappa loci than the heavy chain 14q32/IGH (Aukema et al 2011, Swerdlow et al 2014). Non-IG partners are found in 40%, recurrently involved 19p13, 1q24, 9p13, or non-identified partner regions (Figure 1). Deletions of chromosome 17p13/ TP53 are present in 20-30% of cases, which can further induce genomic instability, and contribute to the aggressive course of the disease (Figure 1).

Cytogenetics molecular

Conventional cytogenetics is not always feasible since fresh tissue is required, and small translocations can be overlooked in a complex karyotype. Therefore, most cases currently are detected by FISH using labeled probes targeting genes of interest. FISH studies can be successfully performed with high reproducibility in almost all cases using formalin-fixed paraffin-embedded tissue sections, although smears, touch imprints, or pellet of metaphase and interphase cells can also be used. Today, most clinical cytogenetic laboratories are using a panel of FISH probes for detection of double hit lymphomas including LSI MYC break-apart (BA), LSI BCL6 BA, and LSI IGH-BCL2 dual fusion translocation probes. The IGH-MYC dual fusion translocation probe is useful in picking up occasional cases missed by the MYC BA probe and also in identifying the MYC partner in a subset of the cases (Figure 2 B). Collectively, FISH is considered the "Gold-Standard" test in identifying DH and TH lymphomas. At present it is a subject of debate, if all DLBCL should have FISH testing to detect MYC, BCL2, and BCL6 rearrangements or should FISH only performed on selected cases with high grade morphology and CG phenotypes. Guidelines are warranted to avoid high cost and at the same time not miss those aggressive lymphomas (Pedersen et al 2012, Sesques and Johnson 2017).
Atlas Image
Figure 2: FISH panel for "double-hit" lymphoma, A; MYC BA probe set showing a split/translocation pattern. B; IGH/MYC,CEP8 tricolor dual fusion translocation probe set showing two fusion signals indicating the presence oft(8;14). C; IGH/BCL2 dual fusion translocation probe set showing two fusion signals indicating t(14;18). D; BCL6 BA probe set showing a split/translocation pattern (all probes purchased from Abbott Molecular Inc, Des Plaines, IL USA).

Genes Involved and Proteins

Gene name
MYC v-myc myelocytomatosis viral oncogene homolog (avian)
Location
8q24.21
Note
Alternative symbols: MYC proto-oncogene, bHLH transcription factor, v-myc avian myelocytomatosis viral oncogene homolog.
Protein description
The product of the MYC gene has a molecular mass of 65 kD, is located predominantly in the nucleus, and binds to DNA. It is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, metabolism, DNA repair, apoptosis and cellular transformation. MYC operates as a transcription factor, being involved in almost every aspect of cell biology. It has been reported to regulate the expression of almost 15% of genes within the human genome. Over expression of MYC is associated with uncontrolled cell growth and metastasis whereas loss of its expression delays growth and promotes differentiation. Some of the most biologically important MYC target genes are cyclins and cyclin-dependent kinases (CDKs), resulting in accelerated cell cycling. Additionally, MYC is involved in the regulation of many micro-RNA (miRNA) expressions, including both the tumor suppressor and the oncogenic miRNAs (Aukema et al 2011, Sesques et al 2017). MYC induces DNA stress and activates the TP53 checkpoint, leading to apoptosis (Hoffman and Liebermann 2008). , BCL6 is widely expressed in many tissues, but in B-cells it is mostly restricted to germinal center B cells. The expression of BCL6 can be demonstrated in tissue sections by IHC. It is present in B-cells of both healthy and neoplastic germinal centers. It therefore demonstrates both reactive hyperplasia in lymph nodes and a range of lymphomas derived from follicular B-cells, such as Burkitts lymphoma, follicular lymphoma, and the nodular lymphocyte predominant subtype of Hodgkins disease. It is often used together with antibodies to Bcl-2 antigen to distinguish neoplastic follicles from those found in benign hyperplasia, for which Bcl-2 is negative.
Gene name
BCL2 (B-cell leukemia/lymphoma 2)
Location
18q21.33
Note
Alternative symbol: Apoptosis regulator; B-cell leukemia/lymphoma 2.
Protein description
BCL2 protein is the most potent member of a large BCL2 family which regulate cell death (apoptosis), by either inducing pro-apoptotic proteins or inhibiting apoptosis. BCL2 is widely expressed in immature B cells and memory B cells but is down-regulated in GC B cells, partially because of repression by BCL6. It is localized to the outer membrane of mitochondria, where it plays an important role in promoting cellular survival and inhibiting the actions of pro-apoptotic proteins. The pro-apoptotic proteins in the BCL-2 family, including BAX and BAK1, normally act on the mitochondrial membrane to promote permeabilization and release of cytochrome C and ROS1 that are important signals in the apoptosis cascade. These pro-apoptotic proteins are inhibited by the function of BCL2.
Gene name
BCL6 (B-Cell Lymphoma 6)
Location
3q27.3
Note
Alternative symbols: B-cell lymphoma 6; Zinc finger protein 51 (ZNF51).
Protein description
The protein encoded by this gene is a zinc finger transcription factor and contains an N-terminal POZ domain. This protein acts as a sequence-specific repressor of transcription, and has been shown to modulate the transcription of STAT-dependent IL-4 responses of B cells. It can interact with a variety of POZ-containing proteins that function as transcription corepressors. BCL6 functions as a transcriptional repressor of many target genes involved in apoptosis, DNA damage response, cell cycle control, proliferation, and differentiation. These genes are BCL2, TP53, IRF4, and PRDM1 (BLIMP1), the latter being essential for maturation into plasma cells. As a result of the BCL6-mediated repression of TP53, somatic hypermutation and class switch recombination are facilitated. Approximately 30% of diffuse large cell lymphomas and 10% of follicular lymphomas have 3q27 chromosomal translocations that upregulate expression of BCL6 by juxtaposing to IG or non-IG promoters to the BCL6 coding domain.

Result of the Chromosomal Anomaly

Note

MYC translocations, a biological hallmark of BL, can also be detected in other B-cell lymphomas DLBCL, BCLU, and FL but at lower frequencies (mohamed et al 2001). However, there are some fundamental differences between MYC translocation in BL and in other mature B-cell lymphomas. In BL the MYC translocation always involves one of the IG genes, (IGH, IGL or IGK) and is considered a disease-initiating event which occurs in the context of a rather simple karyotype (Dave et al 2006). In contrast, MYC translocations in other mature B-cell lymphomas frequently involve non-IG partners and are mostly found in complex karyotypes, often in addition to well-known primary aberrations such as t(14;18) or t(3;14) translocation. In these lymphomas, MYC translocation is considered as a secondary event occurs during disease progression. Dave et al reported that the gene expression of MYC translocations in BL tend to be simple and control several genes involved in proliferation. In contrast, MYC aberrations in DLBCL-targeted genes are associated with nuclear factor kB (NF-kB) signaling and antiapoptotic cascades. Other mechanisms of MYC deregulation in aggressive B-cell lymphomas are mutations, increase copy number and transcriptional upregulation, mainly by B-cell receptor and NF-kB signaling. Recent studies show that microRNAs may upregulate MYC expression. In clinical setting, MYC aberrations can be detected by conventional cytogenetics, FISH, and recently by IHC.
In t(14;18) follicular lymphoma, the transcription of BCL2 is "constitutively" upregulated that leads to a survival advantage of the involved B cells. BCL2 overexpression in B cells also leads to impaired DNA repair by blocking nonhomologous end-joining activities of Ku proteins essential for repair of both RAG1 / RAG2 - and AICDA -mediated breakpoints. The t(14;18) is thought to occur early in B-cell development however, it is insufficient to cause follicular lymphoma because t(14;18) is rarely observed as a sole karyotypic abnormality (Mohamed et al 2001) and also can be found in mature B cells in healthy individuals. The over-expression of BCL2 makes the cells susceptible for additional genomic alterations such as MYC or BCL6 mutation and rearrangement. BCL2 protein is detected in over 50% of DLBCL and in 75% of HGBL, but is not expressed in BL.

Highly cited references

Pubmed IDYearTitleCitations
357326082022[Over-expression of NUDT21 inhibits the proliferation of HCT-116 colon cancer cells via blocking P53/CDK2/Rb pathway].0
357261292022Signal and measurement considerations for human translation of diffuse in vivo flow cytometry.0
357199912022Development and Validation of a Prognostic Model to Predict the Prognosis of Patients With Retroperitoneal Liposarcoma: A Large International Population-Based Cohort Study.0
357191682022Bio-Electrical Impedance Analysis: A Valid Assessment Tool for Diagnosis of Low Appendicular Lean Mass in Older Adults?0
357179012022The reliability and validity of the Turkish version of the dual-task questionnaire in patients with multiple sclerosis.0
357149712022Molecular characterization and functional analysis of Esr1 and Esr2 in gonads of Chinese soft-shelled turtle (Pelodiscus sinensis).0
357104542022Determination of puberty in gilts: contrast of diagnostic methods.0
357102902022Temporal trends of aortic stenosis and comorbid chronic kidney disease in the province of Quebec, Canada.0
357000232022Impact of a Papillomavirus Vaccination Promotion Program in Middle School: Study Protocol for a Cluster Controlled Trial.0
356881022022Screen-printed Graphite Electrode Modified with Co3O4Nanoparticles and 2D Graphitic Carbon Nitride as an Effective Electrochemical Sensor for 4-Aminophenol Detection.0
356879002022Cost and Cost Savings of Navigation Services to Avoid Rehospitalization for a Comorbid Substance Use Disorder Population.0
356835652022Health-Screening-Based Chronic Obstructive Pulmonary Disease and Its Effect on Cardiovascular Disease Risk.0
356710712022Hearing Loss in Patients With Morquio Syndrome: Protocol for a Scoping Review.0
356700402022An outbreak of Burkholderia cepacia bloodstream infections in a tertiary-care facility in northern India detected by a healthcare-associated infection surveillance network.0
356664902022Prediction of bowel management independence after ischemic spinal cord injury.0
356553962022Body composition index obtained by using a bioelectrical impedance analysis device can be a predictor of prolonged operative time in patients undergoing minimally invasive colorectal surgery.0
356505842022Investigating the relationship between satisfaction of basic psychological needs, general health, and some background variables in the Iranian older adults: a cross-sectional study.0
355994292022An Opto- and Thermal-Rewrite PCM/CNF-IR 780 Energy Storage Nanopaper with Mechanical Regulated Performance.0
355805632022Optical properties of copper helical nanostructures: the effect of thickness on the SPR peak position.0
355236632022Impact of blood transfusion on survival after nephrectomy for localized or locally advanced renal cancer.0
354395362022Involvement of NLRP3/Caspase-1/GSDMD-Dependent pyroptosis in BPA-Induced apoptosis of human neuroblastoma cells.0
354204262022Systematic Review of Aptamer Sequence Reporting in the Literature Reveals Widespread Unexplained Sequence Alterations.0
354169422022A brain atlas of axonal and synaptic delays based on modelling of cortico-cortical evoked potentials.0
353489742022Multi-omics analyses provide novel biological insights to distinguish lobular ductal types of invasive breast cancers.1
353447662022BFENet: A two-stream interaction CNN method for multi-label ophthalmic diseases classification with bilateral fundus images.0
353036402022Hierarchical multi-yolk-shell copper oxide@copper-1, 3, 5-benzenetricarboxylate as an ultrastable anode for lithium ion batteries.0
352487272022Methylene blue and carbon nanoparticles had no significant adverse effects on the survival and function of lymph nodes after non-vascularized transplantation in a mouse model.0
352280762022Fabrication and investigation of novel monochloroacetic acid fortified, tripolyphosphate-crosslinked chitosan for highly efficient adsorption of uranyl ions from radioactive effluents.0
351969162022Validation of the Wisconsin upper respiratory symptom survey-24, Chinese version.0
351822052022Clinical and therapeutic variables may influence the association between infarct core predicted by CT perfusion and clinical outcome in acute stroke.0
350919282022Occurrence and behavior of uranium and thorium series radionuclides in the Permian shale hydraulic fracturing wastes.0
350845192022Proximal nerve MR neurography with diffusion tensor imaging in differentiating subtypes of Charcot-Marie-Tooth disease.0
350592902022Traditional Chinese medicine attenuates hospitalization and mortality risks in diabetic patients with carcinoma in situ in Taiwan.0
350249122022Risk factors of persistent subretinal fluid after half-dose photodynamic therapy for treatment-naïve central serous chorioretinopathy.0
347469552022Effect of 5 years of exercise training on the cardiovascular risk profile of older adults: the Generation 100 randomized trial.1
347241452022Scoring model to predict risk of chronic kidney disease in Chinese health screening examinees with type 2 diabetes.0
345537802022Fully Automated Placental Volume Quantification From 3D Ultrasound for Prediction of Small-for-Gestational-Age Infants.0
344276932022The effect of Covid-19 on the willingness to use video consultations among orthopedic and trauma outpatients: a multi-center survey in 1400 outpatients.1
341559392022Heliox for Pediatric Critical Asthma: A Multicenter, Retrospective, Registry-Based Descriptive Study.0
357314362022Integrating CVOR-GWLR-Circuit model into construction of ecological security pattern in Yunnan Province, China.0
357297492022A Hybrid Functional Study on Perovskite-Based Compounds CsPb1-αZnαI3-βXβ (X = Cl or Br).0
357207192022Deep Learning-Based Automated Detection of Arterial Vessel Wall and Plaque on Magnetic Resonance Vessel Wall Images.0
357141402022Affordable artificial intelligence-based digital pathology for neglected tropical diseases: A proof-of-concept for the detection of soil-transmitted helminths and Schistosoma mansoni eggs in Kato-Katz stool thick smears.0
357060632022HIV/AIDS patients undergoing total knee arthroplasty are at higher risk of acute renal failure and transfusion and incurred higher cost: a propensity-matched database study.0
357104292022Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey.0
357090042022Magnusiomyces siamensis sp. nov., a yeast-like fungus isolated from food waste.0
357025142022Perceived risk of contracting COVID-19 among healthcare workers in Ghana: A cross-sectional study.0
356997662022Prophylactic Enoxaparin Against Catheter-Associated Thrombosis in Postoperative Cardiac Children: An Interrupted Time Series Analysis.0
356953252022Opinions of nursing and theology faculty students on Xenotransplantation.0
356945832022MiR-186-5p Downregulates NAMPT and Functions as a Potential Therapeutic Target for Sepsis-Induced Coagulation Disorders.0
356888832022Influence of sintering temperatures on microstructure and electrochemical performances of LiNi0.93Co0.04Al0.03O2 cathode for high energy lithium ion batteries.0
356798332022Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer - A Retrospective, Single Institution Experience.0
356729032022Monocyte-to-lymphocyte ratio: a potential novel predictor for acute kidney injury in the intensive care unit.0
356725222022Pilot Report for Intracranial Hemorrhage Detection with Deep Learning Implanted Head Computed Tomography Images at Emergency Department.0
356710562022Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma.0
356577262022Role of a conserved ion-binding site tyrosine in ion selectivity of the Na+/K+ pump.0
356576202022Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity.0
356212042022Cerebral Circulation Time After Thrombectomy: A Potential Predictor of Outcome After Recanalization in Acute Stroke.0
355949742022Associations between screen time and internalizing disorder diagnoses among 9- to 10-year-olds.0
355881882022Transfer Patterns of Very Low Birth Weight Infants for Convalescent Care.0
355079732022Chitosan with pendant (E)-5-((4-acetylphenyl)diazenyl)-6-aminouracil groups as synergetic antimicrobial agents.0
354895302022Assessing the effect of fine particulate matter on adverse birth outcomes in Huai River Basin, Henan, China, 2013-2018.0
354834572022Predicting reaction rate constants of ozone with ionic/non-ionic compounds in water.0
354712602022Quebec Health-related Quality of Life Population Norms in Adults Using the SF-6Dv2: Decomposition by Sociodemographic Data and Health Problems.0
354054432022Inhibitory effects of estrogenic endocrine disrupting chemicals on fin regeneration in zebrafish are dependent on estrogen receptors.0
354036862022Decline in attention-deficit hyperactivity disorder traits over the life course in the general population: trajectories across five population birth cohorts spanning ages 3 to 45 years.0
354004982022Breeding value reliabilities for multiple-trait single-step genomic best linear unbiased predictor.0
353943932022Impact of preovulatory estradiol concentrations on subsequent luteal function in beef cattle.0
353941032022RAFT Polymerization of Semifluorinated Monomers Mediated by a NIR Fluorinated Photocatalyst.0
353815112022Golf-shaped Bi2Se3 microparticles based-immunochromatographic strip for ultrasensitive detection of Acetamiprid.0
353638812022A comparison of local therapy alone with local plus systemic therapy for stage I pT1aN0M0 HER2+ breast cancer: A National Cancer Database analysis.0
353442102022Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia.0
353386642022Attitudes Toward Telehealth Services Among People Living With Parkinson's Disease: A Survey Study.0
353182182022Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries.0
353050272022An original deep learning model using limited data for COVID-19 discrimination: A multicenter study.0
352975592022Age and sex differences on the association between anxiety disorders and obstructive sleep apnea: A nationwide case-control study in Taiwan.0
352029882022A new amine moiety-based near-infrared fluorescence probe for detection of formaldehyde in real food samples and mice.0
351751592022Usefulness of complete blood count parameters to predict poor outcomes in cancer patients with febrile neutropenia presenting to the emergency department.0
351688812022Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer.1
351132132022CT-based radiomics for differentiating intracranial contrast extravasation from intraparenchymal haemorrhage after mechanical thrombectomy.0
350601322022Human papillomavirus genotype concordance between Anyplex II HPV28 and linear array HPV genotyping test in anogenital samples.0
350582082022Comparison Between Franz Diffusion Cell and a novel Micro-physiological System for In Vitro Penetration Assay Using Different Skin Models.2
350001012022Measuring Evidence-Based Treatment Strategies in Youth Community Mental Health Care: the Evidence-Based Strategies Scale.0
349973912022A Cohort Analysis of Statin Treatment Patterns Among Small-Sized Primary Care Practices.0
348115102022Non-anemic iron deficiency: correlations between symptoms and iron status parameters.0
344530262022Sitting Time, Physical Activity, and Cognitive Impairment in Midlife and Older Adults.0
357368962022The Mixture of Bisphenol-A and Its Substitutes Bisphenol-S and Bisphenol-F Exerts Obesogenic Activity on Human Adipose-Derived Stem Cells.0
357223752022Development and validation of a machine-learning model for prediction of hypoxemia after extubation in intensive care units.0
357205702022RAD-Seq-Based High-Density Linkage Maps Construction and Quantitative Trait Loci Mapping of Flowering Time Trait in Alfalfa (Medicago sativa L.).0
357204862022Bladder cancer cell lines adapt their aggressiveness profile to oxygen tension.0
356816432022Dual-Intended Deep Learning Model for Breast Cancer Diagnosis in Ultrasound Imaging.0
356816392022Rescue Surgery after Immunotherapy/Tyrosine Kinase Inhibitors for Initially Unresectable Lung Cancer.0
356769152022Metabolic Profile of Sow Blood Serum after Weaning.0
356554862022DCAF12 and HSPA1A May Serve as Potential Diagnostic Biomarkers for Myasthenia Gravis.0
3564625120222020 Annual Report of the Kansas Poison Control Center at The University of Kansas Health System.0
356449762022[Evaluation of the effect of comprehensive prevention and management of diabetes mellitus of two cross-sectional surveys based on community population].0
356364802022Alarming Trends: Mortality from Alcoholic Cirrhosis in the United States.0
356296532022Influence of Different Welding Parameters on the Morphology, Microstructure, and Mechanical Properties of 780 Duplex-Phase Steel Laser Lap Welded Joint.0
356291772022Important Risk Factors in Patients with Nonvalvular Atrial Fibrillation Taking Dabigatran Using Integrated Machine Learning Scheme-A Post Hoc Analysis.0
356272512022Capturing Genetic Diversity and Selection Signatures of the Endangered Kosovar Balusha Sheep Breed.0

Bibliography

Pubmed IDLast YearTitleAuthors
211191072011Double-hit B-cell lymphomas.Aukema SM et al
204984062010Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.Barrans S et al
213009842011The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.Campo E et al
167604432006Molecular diagnosis of Burkitt's lymphoma.Dave SS et al
266347082015Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.Dunleavy K et al
223141912012High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma.Green TM et al
226655372012Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.Green TM et al
189559732008Apoptotic signaling by c-MYC.Hoffman B et al
254312382015Scoring of MYC protein expression in diffuse large B-cell lymphomas: concordance rate among hematopathologists.Mahmoud AZ et al
113437782001Chromosomal analyses of 52 cases of follicular lymphoma with t(14;18), including blastic/blastoid variant.Mohamed AN et al
249431072014Double hit lymphoma: the MD Anderson Cancer Center clinical experience.Oki Y et al
280617822017Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma.Oliveira CC et al
225101492012Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience.Pedersen MØ et al
245062002014MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.Perry AM et al
250605882014MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.Petrich AM et al
278215092017Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements.Sesques P et al
256968402014Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.Swerdlow SH et al
269807272016The 2016 revision of the World Health Organization classification of lymphoid neoplasms.Swerdlow SH et al

Summary

Note

The "double-hit" lymphoma is a genotype feature of lymphoma that exhibits translocations of both the MYC /8q24 gene and a second site, most often the BCL2 /18q21 or less commonly the BCL6 /3q27 gene. A rare "triple-hit" lymphoma harboring MYC, BCL2, and BCL6 translocations has also been identified. Cytogenetics is necessary in establishing the diagnosis of these lymphomas as they tend to manifest an aggressive behavior, and poor outcome when treated with standard therapy.

Citation

Anwar N Mohamed

Double Hit Lymphoma (DHL)
Triple Hit Lymphoma (THL)

Atlas Genet Cytogenet Oncol Haematol. 2017-04-01

Online version: http://atlasgeneticsoncology.org/haematological/1613/double-hit-lymphoma-(dhl)-br-triple-hit-lymphoma-(thl)

External Links